The “Unexpected” Reason Why COVID Antivirals Don’t Work

Tara Fernandez
Apr 13 · 2 min read

The coronavirus triggers a unique inflammatory pathway in the lungs

Image via Pexels

Purdue University researchers have made a breakthrough finding that could explain why the disease is so hard to manage therapeutically. In what was described as a surprising discovery, they found that a specific immune pathway activated in the lung tissue during COVID infection contributes to hyper-inflammation in severe cases, rendering standard antivirals ineffective.

Since the beginning of the pandemic, scientists have been scrambling to identify antiviral drugs to treat COVID patients with severe and life-threatening symptoms. Unfortunately, until now, this search has dug up very few viable options. Antivirals such as Remdesivir and Ruxolitinib are notoriously ineffective at treating COVID patients.

To understand why these drugs fall short, Purdue University computer science expert Majid Kazemian and colleagues took a closer look at the gene expression fingerprints left by SARS-CoV-2 infections. The team made the unexpected observation that small immune proteins, typically synthesized by the liver, were being produced in the fine structures of the lung known as alveoli. These proteins, part of the immune complement system, normally help the antibodies combat infectious pathogens.

“We observed that SARS-CoV2 infection of these lung cells causes expression of an activated complement system in an unprecedented way,” explained Kazemian.

“This was completely unexpected to us because we were not thinking about activation of this system inside the cells, or at least not lung cells. We typically think of the complement source as the liver.”

However, instead of protecting against the coronavirus, complement activation in the lung triggers uncontrolled and detrimental tissue hyper-inflammation, a trademark symptom of severe COVID-19.

These findings provide evidence for why targeting inflammation outside the lungs has been disappointing so far. Instead, a more targeted approach that inhibits the expression and activation of complement proteins in lung cells could yield better results. For example, the researchers found that pairing Remdesivir with Ruxolitinib inhibited the complement response much more effectively than a monotherapy of the drugs independently, using an in vitro model of alveolar cells.

Despite the promising preliminary data, follow-up experiments are needed to determine whether such drug combos would work well in patients.

Sources:Science Immunology, Purdue University.

Originally published at https://www.labroots.com on April 14, 2021.

The Reading Frame

Bite-sized stories on science, technology, and innovation.

Sign up for The Reading Frame

By The Reading Frame

A roundup of stories from the leading edge of science, medicine, and technology. Take a look.

By signing up, you will create a Medium account if you don’t already have one. Review our Privacy Policy for more information about our privacy practices.

Check your inbox
Medium sent you an email at to complete your subscription.

Tara Fernandez

Written by

Cat person, PhD-qualified Cell Biologist & Science Writer. Interested in trends and emerging technologies in the biopharma industry.

The Reading Frame

The Reading Frame highlights breakthroughs at the leading edge of science, technology, and innovation.

Tara Fernandez

Written by

Cat person, PhD-qualified Cell Biologist & Science Writer. Interested in trends and emerging technologies in the biopharma industry.

The Reading Frame

The Reading Frame highlights breakthroughs at the leading edge of science, technology, and innovation.

Medium is an open platform where 170 million readers come to find insightful and dynamic thinking. Here, expert and undiscovered voices alike dive into the heart of any topic and bring new ideas to the surface. Learn more

Follow the writers, publications, and topics that matter to you, and you’ll see them on your homepage and in your inbox. Explore

If you have a story to tell, knowledge to share, or a perspective to offer — welcome home. It’s easy and free to post your thinking on any topic. Write on Medium

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store